Literature DB >> 17299514

Clozapine blocks D-amphetamine-induced excitation of dopamine neurons in the ventral tegmental area.

Wei-Xing Shi1, Xiang-Yang Zhang, Chen-Lun Pun, Benjamin S Bunney.   

Abstract

Current antipsychotic drugs are thought to inhibit central dopamine (DA) transmission by blocking DA receptors. Here, we provide evidence that the atypical antipsychotic drug clozapine may produce part of its effect by inhibiting a subset of excitatory inputs to DA neurons. Thus, in chloral hydrate-anesthetized rats, systemic administration of D-amphetamine produced two opposing effects on DA neurons in the ventral tegmental area. Under control conditions, D-amphetamine inhibited the firing of the cell through D2-like receptors. When D2-like receptors were blocked by raclopride, D-amphetamine excited DA neurons, instead of producing no effect. The excitation, expressed as an increase in firing rate and a slow oscillation in firing pattern, was suppressed by the adrenergic alpha1 receptor antagonist prazosin, suggesting an involvement of alpha1 receptors. In rats pretreated with the typical antipsychotic drug haloperidol, D-amphetamine also excited DA neurons. However, when given after clozapine, D-amphetamine produced no significant effects. The failure of D-amphetamine to produce an excitation is not due to an incomplete blockade of D2-like receptors by clozapine because co-treatment with clozapine and raclopride also failed to enable the excitatory effect of D-amphetamine. The suggestion that clozapine inhibits the excitatory effect of D-amphetamine is further supported by the finding that clozapine, given after D-amphetamine, reliably reversed D-amphetamine-induced excitation in raclopride-treated rats. Thus, different from raclopride and haloperidol, clozapine may inhibit DA transmission through two additive mechanisms: blockade of DA receptors and inhibition of an amphetamine-sensitive, excitatory pathway that innervates DA neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299514     DOI: 10.1038/sj.npp.1301334

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

1.  In vivo comparison of norepinephrine and dopamine release in rat brain by simultaneous measurements with fast-scan cyclic voltammetry.

Authors:  Jinwoo Park; Pavel Takmakov; R Mark Wightman
Journal:  J Neurochem       Date:  2011-10-20       Impact factor: 5.372

2.  Methamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currents.

Authors:  Sarah Y Branch; Michael J Beckstead
Journal:  J Neurophysiol       Date:  2012-05-16       Impact factor: 2.714

3.  Mechanisms involved in systemic nicotine-induced glutamatergic synaptic plasticity on dopamine neurons in the ventral tegmental area.

Authors:  Ming Gao; Yu Jin; Kechun Yang; Die Zhang; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

Review 4.  Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms.

Authors:  Ike Dela Peña; Ruzanna Gevorkiana; Wei-Xing Shi
Journal:  Eur J Pharmacol       Date:  2015-07-21       Impact factor: 4.432

Review 5.  Heterogeneity of dopamine neuron activity across traits and states.

Authors:  M Marinelli; J E McCutcheon
Journal:  Neuroscience       Date:  2014-07-30       Impact factor: 3.590

6.  Functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area.

Authors:  Ming Gao; Chang-Liang Liu; Shen Yang; Guo-Zhang Jin; Benjamin S Bunney; Wei-Xing Shi
Journal:  J Neurosci       Date:  2007-05-16       Impact factor: 6.167

7.  Distinct dose-dependent effects of methamphetamine on real-time dopamine transmission in the rat nucleus accumbens and behaviors.

Authors:  Rohan V Bhimani; Megan Vik; Ken T Wakabayashi; Caitlin Szalkowski; Caroline E Bass; Jinwoo Park
Journal:  J Neurochem       Date:  2021-07-28       Impact factor: 5.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.